B2i Digital, Inc. has announced the Life Sciences Virtual Investor Forum, a two-day event taking place June 24 and 25, 2026, co-hosted by Virtual Investor Conferences and Zacks Small-Cap Research. The forum will feature 23 presenting companies spanning clinical-stage biotechnology, rare-disease and oncology therapeutics, molecular diagnostics, medical devices, veterinary medicine, nutrition science, and AI-powered digital health, according to a press release.
As the Official Marketing Partner, B2i Digital brings the forum into its ecosystem, leveraging a distribution and media engine that drives qualified investors to presentations and one-on-one meetings. The company amplifies the event across its platform, reaching a proprietary network of more than 1.7 million retail and institutional market participants. B2i Digital has carried more than 115 investor conferences, according to David Shapiro, Chief Executive Officer of B2i Digital.
Zacks Small-Cap Research, a preferred provider in the OTC Markets Group's Research Marketplace, prepares independent company-sponsored research and supports the forum as co-host. Its team of life sciences analysts adds value for investors, Shapiro noted.
Each company will have 30 minutes for a live presentation and real-time Q&A session. One-on-one meeting requests are available through the VIC site, with replays posted on B2i Digital and OTC Markets YouTube channels. Investors can register and view company profiles at the Virtual Investor Conferences registration page.
Day one on June 24 includes Protalix BioTherapeutics, MetaVia Inc., CytoSorbents Corporation, PetVivo Holdings Inc., Jaguar Health, Inc., Reviva Pharmaceuticals Holdings, Inc., and 4DMedical Ltd. Day two on June 25 features Prostatype Genomics AB, Abingdon Health plc, Innovotech, Inc., Lakewood-Amedex Biotherapeutics Inc., Nasus Pharma Ltd., Kelyniam Global, Inc., IMUNON, Inc., Promino Nutritional Sciences Inc., Envoy Medical Inc., Coiled Therapeutics plc, Aspire Biopharma Holdings Inc., Rocket Doctor AI Inc., Phio Pharmaceuticals Corp., aTyr Pharma, Inc., and NuFarm Ltd.
“Life sciences investors want efficient, direct access to management teams developing the therapies and technologies that matter, and pairing that access with independent research from Zacks makes the forum more valuable on both sides,” Shapiro said. “Over two days, investors can meet companies across biotech, diagnostics, devices, and digital health, and reach their own conclusions.”
Virtual Investor Conferences is a property of OTC Markets Group Inc. Throughout the year, the conferences feature public companies from exchanges worldwide, including NYSE, Nasdaq, TSX, TSXV, CSE, ASX, LSE, and the OTC Markets.
The forum underscores the growing trend of virtual access to life sciences investment opportunities, providing a platform for investors to engage directly with management without geographical constraints. For more details, visit B2i Digital's event page.
